AxoGen (NASDAQ:AXGN - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "hold" rating to a "strong-buy" rating in a research report issued on Saturday, Wall Street Zen reports.
AXGN has been the subject of a number of other research reports. Canaccord Genuity Group lifted their price target on AxoGen from $55.00 to $60.00 and gave the company a "buy" rating in a research note on Thursday. Morgan Stanley downgraded AxoGen to a "hold" rating in a research note on Tuesday, September 29th. Weiss Ratings restated a "sell (d-)" rating on shares of AxoGen in a report on Wednesday, August 26th. Jefferies Financial Group reaffirmed a "buy" rating and set a $60.00 target price on shares of AxoGen in a research report on Wednesday. Finally, Citizens Jmp upped their price target on AxoGen from $50.00 to $55.00 and gave the stock a "market outperform" rating in a report on Thursday, July 30th. Thirteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $57.92.
Get Our Latest Stock Report on AxoGen
AxoGen Stock Down 0.5%
AxoGen stock opened at $49.37 on Friday. The firm has a market capitalization of $2.95 billion, a price-to-earnings ratio of -75.95 and a beta of 1.17. The firm's fifty day moving average price is $42.86 and its two-hundred day moving average price is $39.45. AxoGen has a 1-year low of $21.68 and a 1-year high of $52.91. The company has a current ratio of 12.02, a quick ratio of 5.04 and a debt-to-equity ratio of 0.04.
AxoGen (NASDAQ:AXGN - Get Free Report) last posted its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.21 EPS for the quarter, topping the consensus estimate of $0.13 by $0.08. AxoGen had a negative net margin of 11.96% and a negative return on equity of 5.35%. The company had revenue of $75.83 million during the quarter, compared to the consensus estimate of $73.45 million. On average, equities research analysts predict that AxoGen will post -0.44 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other news, Director Joseph Tyndall sold 3,500 shares of AxoGen stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $49.70, for a total transaction of $173,950.00. Following the sale, the director directly owned 10,650 shares in the company, valued at $529,305. The trade was a 24.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathy Weiler sold 14,150 shares of AxoGen stock in a transaction on Friday, August 7th. The stock was sold at an average price of $45.30, for a total value of $640,995.00. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 98,503 shares of company stock valued at $4,656,947. 2.44% of the stock is owned by company insiders.
Institutional Trading of AxoGen
Several hedge funds have recently added to or reduced their stakes in the stock. State of Alaska Department of Revenue increased its stake in shares of AxoGen by 16.9% during the third quarter. State of Alaska Department of Revenue now owns 2,833 shares of the medical equipment provider's stock valued at $118,000 after buying an additional 409 shares during the period. PNC Financial Services Group Inc. lifted its stake in AxoGen by 6.2% in the first quarter. PNC Financial Services Group Inc. now owns 8,943 shares of the medical equipment provider's stock worth $296,000 after acquiring an additional 525 shares during the period. Nykredit A S purchased a new stake in AxoGen in the second quarter worth $30,000. Arizona State Retirement System lifted its stake in AxoGen by 7.6% in the second quarter. Arizona State Retirement System now owns 13,604 shares of the medical equipment provider's stock worth $628,000 after acquiring an additional 966 shares during the period. Finally, Principal Financial Group Inc. boosted its holdings in AxoGen by 1.4% in the first quarter. Principal Financial Group Inc. now owns 89,745 shares of the medical equipment provider's stock valued at $2,973,000 after acquiring an additional 1,210 shares in the last quarter. Institutional investors own 80.29% of the company's stock.
Key Headlines Impacting AxoGen
Here are the key news stories impacting AxoGen this week:
- Positive Sentiment: Strong Q3 execution and higher guidance: AxoGen reported 26% revenue growth and 45% adjusted EBITDA growth for the third quarter of 2026. Management maintained a target of at least $290 million in 2026 sales and expects gross margin of 73% or higher, reinforcing the company’s growth and operating-leverage story. AxoGen Third-Quarter Earnings Results
- Positive Sentiment: Analysts raised their targets: Canaccord Genuity increased its price target to $60 from $55 and maintained a Buy rating. Truist also raised its target to $60 from $53, while Wells Fargo increased its target to $56 from $48 and kept an Overweight rating. HC Wainwright lifted its target to $56 from $53 and retained a Buy rating. These revisions indicate improving confidence in AxoGen’s earnings outlook. Truist AxoGen Price Target Update
- Positive Sentiment: BioCircuit acquisition expands the opportunity: An investment analysis characterized AxoGen as evolving toward a leading procedural platform in peripheral nerve repair. The planned $200 million BioCircuit, or NerveTape, acquisition is intended to reduce technical barriers for surgeons, broaden the addressable market and be accretive at an estimated 5.9 times 2027 sales. AxoGen Taking the Friction Out of Nerve Repair
- Neutral Sentiment: Valuation remains an investor debate: Coverage is focused on whether AXGN’s growth prospects justify its elevated valuation after its substantial advance. The stock’s performance relative to other medical companies may attract momentum investors, but also raises the risk that much of the near-term optimism is already reflected in the share price. Does AxoGen Have More Upside?
- Negative Sentiment: Profitability and execution risks remain: Despite improving adjusted EBITDA, AxoGen continues to report negative net income and analysts expect a full-year loss. Investors must also weigh acquisition integration, dilution and the company’s premium valuation against the possibility of slower growth.
About AxoGen
(
Get Free Report)
AxoGen, Inc NASDAQ: AXGN is a medical technology company focused on developing and commercializing products for the repair and regeneration of peripheral nerves. Its technologies are designed to help restore sensory and motor function following traumatic injuries, surgical procedures, and other conditions affecting peripheral nerves.
The company's product portfolio includes Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves without requiring tissue to be taken from another part of the patient's body.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AxoGen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AxoGen wasn't on the list.
While AxoGen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.